Analysts Endorse Ranbaxy-Pfizer Deal On Lipitor
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Analysts have backed the settlement deal between Ranbaxy Laboratories and Pfizer on the latter's blockbuster cholesterol-lowering drug Lipitor (atorvastatin) calling it a "very positive" development for the Indian drug maker